Moderna, Inc. (MRNA)
3 Biotech Stocks With Massive Upside to Buy Before August Starts
Biotech is setting up as one of the more interesting risk-on trades heading into the back half of 2026.
2 Major Reasons to Buy Moderna Stock Before July 31
Moderna (NASDAQ:MRNA | MRNA Price Prediction) enters a critical six-day stretch with Q2 earnings due July 31, and an FDA decision on its seasonal flu vaccine expected August 5.
Moderna (MRNA) Laps the Stock Market: Here's Why
In the most recent trading session, Moderna (MRNA) closed at $55.63, indicating a +2.89% shift from the previous trading day.
Will Moderna (MRNA) Report Negative Earnings Next Week? What You Should Know
Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Moderna (MRNA) Suffers a Larger Drop Than the General Market: Key Insights
In the most recent trading session, Moderna (MRNA) closed at $59.49, indicating a -3.77% shift from the previous trading day.
MRNA Advances Cancer Pipeline With New Immunotherapy Study
Moderna doses the first U.S. participant in a phase I study of mRNA-4200, advancing its off-the-shelf cancer therapy pipeline beyond vaccines.
Moderna set for uneventful Q2 report ahead of key data readouts, says Jefferies
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) is expected to report second quarter results on July 31, with investors focused on the impact of seasonal COVID-19 vaccine demand and updates on the company's late-stage pipeline, including anticipated Phase III melanoma data. Jefferies analysts expect a largely uneventful earnings report after Moderna previously guided for second-quarter revenue of $50 million to $100 million, down from $389 million in the first quarter, reflecting the seasonal nature of COVID vaccine sales.
Moderna (MRNA) Registers a Bigger Fall Than the Market: Important Facts to Note
Moderna (MRNA) reached $66.98 at the closing of the latest trading day, reflecting a -1.89% change compared to its last close.
Arbutus Biopharma: Moderna Validates My IP Bull Case
Arbutus Biopharma is now much better capitalized after Moderna validated the value of its LNP patents. As for ABUS' in-house assets, I think Imdusiran has shown durable viral control. The main caveat is that it comes from combo therapies. Their balance sheet gives them a comfortable runway to pursue imdusiran's upcoming Phase 2b trial, which is yet another optionality vertical for the stock.
Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout
Biotech is the story at midday Friday, and it's not a pretty one for shareholders who chased the sector's monster 2026 run.
Moderna wins EU contract for RSV vaccine supply
Moderna said on Thursday it has secured a European Commission contract to supply its respiratory syncytial virus vaccine to six countries in the region.
Moderna (MRNA) Outpaces Stock Market Gains: What You Should Know
Moderna (MRNA) closed at $81.76 in the latest trading session, marking a +2.51% move from the prior day.
